Penumbra, Inc.

12/23/2025

This holiday season, we’re grateful for all those who drive our innovation forward. Wishing you a wonderful holiday season and a happy New Year!

12/19/2025

US HCPs: A recently published study in the American Journal of Cardiology found that CAVT may help hospitals reduce length of stay, lower complications, and support better outcomes for patients with intermediate-risk PE. Read more on how could benefit hospital systems and improve patient outcomes: https://peninc.info/4oZZLDF

Rx only. Risk info: http://peninc.info/risk Clinical results may vary.

11/25/2025

Hear from Dr. Lookstein, Co-Principal Investigator of the -PE , as he discusses the study’s primary endpoints and what these results mean for advancing PE treatment. Learn more here: https://www.penumbrainc.com/storm-pe-rct/

11/25/2025

From adrenaline-filled adventures to everyday impact, Lily Lim thrives on challenges that make a difference. Discover how this senior territory manager combines bold choices with a passion for improving lives. Read more here: https://peninc.info/4rsYBDd. If you’d like to join our team, visit https://bit.ly/3z6E0Kx to learn more about career opportunities.

11/20/2025

US HCPs: He faked a heart attack to save his life. Now he’s helping change how we treat pulmonary embolism.

Read Richard Davis’s story of survival, advocacy, and impact on the STORM-PE RCT trial: https://peninc.info/43INYBI

11/11/2025

US HCPs: New analyses from the STRIKE-PE study presented at show that CAVT technology was associated with improved functional outcomes and quality of life for patients with intermediate- and high-risk pulmonary embolism. Read more about the findings here: https://peninc.info/3WSQ4v9

Rx only. Risk info: http://peninc.info/risk Clinical results may vary.

11/06/2025

US HCPs: now published in Circulation! Backed by peer-reviewed level 1 evidence for the treatment of acute intermediate high-risk PE, shows superior efficacy over anticoagulation alone. Read more here: https://www.ahajournals.org/doi/10.1161CIRCULATIONAHA.125.077232

Rx only. Please go to peninc.info/risk for the complete IFU Summary Statements. Clinical results may vary.

11/05/2025

Join us today for our 3rd Quarter Earnings Conference Call at 1:30pm PT / 4:30pm ET. For more information: https://peninc.info/3JvXuRO.

11/03/2025

Penumbra announces secondary results of the ground-breaking STORM-PE RCT at VIVA 2025. Read more here: https://peninc.info/3JuPTDe.

10/30/2025

US HCPs: results challenge the long-standing use of AC alone as the standard of care for acute intermediate high-risk PE. Thank you, investigators, patients, & their families, for helping advance PE care for all! https://peninc.info/storm

Rx only. Please go to peninc.info/risk for the complete IFU Summary Statements. Clinical results may vary.

10/29/2025

On , we join forces with SLICE Worldwide as a Diamond Partner to advance stroke care. Register for 7 expert-led episodes exploring the latest treatments and innovations: https://peninc.info/47dUWRv.

Penumbra joins SLICE Worldwide 2025 as a Diamond Partner!

𝘗𝘦𝘯𝘶𝘮𝘣𝘳𝘢, 𝘐𝘯𝘤, 𝘩𝘦𝘢𝘥𝘲𝘶𝘢𝘳𝘵𝘦𝘳𝘦𝘥 𝘪𝘯 𝘈𝘭𝘢𝘮𝘦𝘥𝘢, 𝘊𝘢𝘭𝘪𝘧𝘰𝘳𝘯𝘪𝘢, 𝘪𝘴 𝘢 𝘨𝘭𝘰𝘣𝘢𝘭 𝘩𝘦𝘢𝘭𝘵𝘩𝘤𝘢𝘳𝘦 𝘤𝘰𝘮𝘱𝘢𝘯𝘺 𝘧𝘰𝘤𝘶𝘴𝘦𝘥 𝘰𝘯 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘵𝘩𝘦𝘳𝘢𝘱𝘪𝘦𝘴. 𝘗𝘦𝘯𝘶𝘮𝘣𝘳𝘢 𝘥𝘦𝘴𝘪𝘨𝘯𝘴, 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘴, 𝘮𝘢𝘯𝘶𝘧𝘢𝘤𝘵𝘶𝘳𝘦𝘴 𝘢𝘯𝘥 𝘮𝘢𝘳𝘬𝘦𝘵𝘴 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘴 𝘢𝘯𝘥 𝘩𝘢𝘴 𝘢 𝘣𝘳𝘰𝘢𝘥 𝘱𝘰𝘳𝘵𝘧𝘰𝘭𝘪𝘰 𝘵𝘩𝘢𝘵 𝘢𝘥𝘥𝘳𝘦𝘴𝘴𝘦𝘴 𝘤𝘩𝘢𝘭𝘭𝘦𝘯𝘨𝘪𝘯𝘨 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘤𝘰𝘯𝘥𝘪𝘵𝘪𝘰𝘯𝘴 𝘪𝘯 𝘮𝘢𝘳𝘬𝘦𝘵𝘴 𝘸𝘪𝘵𝘩 𝘶𝘯𝘮𝘦𝘵 𝘯𝘦𝘦𝘥𝘴. 𝘗𝘦𝘯𝘶𝘮𝘣𝘳𝘢 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘴 𝘩𝘦𝘢𝘭𝘵𝘩𝘤𝘢𝘳𝘦 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘳𝘴, 𝘩𝘰𝘴𝘱𝘪𝘵𝘢𝘭𝘴 𝘢𝘯𝘥 𝘤𝘭𝘪𝘯𝘪𝘤𝘴 𝘪𝘯 𝘰𝘷𝘦𝘳 100 𝘤𝘰𝘶𝘯𝘵𝘳𝘪𝘦𝘴.

Join us online and explore the daily challenges of caring for stroke patients from the inside.

🗓️ October 29, World Stroke Day
📍 Online
👉 Register for free: https://lnkd.in/eRqkZp2

10/27/2025

Penumbra announces the results of the landmark STORM-PE RCT Trial at . Read more here: https://peninc.info/48Kslo9.